Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Systematic Evaluation of Antibody Modification and ⁸⁹ Zr-Radiolabeling for Optimized Immuno-PET.

Autor: Sharma SK; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States., Glaser JM; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States., Edwards KJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States., Khozeimeh Sarbisheh E; Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N-5C9, Canada., Salih AK; Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N-5C9, Canada., Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.; Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.; Department of Pharmacology, Weill Cornell Medical College, New York, New York 10065, United States.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.; Department of Radiology, Weill Cornell Medical College, New York, New York 10065, United States., Price EW; Department of Chemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N-5C9, Canada.

Publikováno v: Bioconjugate chemistry [Bioconjug Chem] 2021 Jul 21; Vol. 32 (7), pp. 1177-1191. Date of Electronic Publication: 2020 Apr 01.

Good practices for ⁸⁹Zr radiopharmaceutical production and quality control.

Autor: Wuensche, Thomas Erik¹ (AUTHOR) t.wunsche@amsterdamumc.nl, Lyashchenko, Serge² (AUTHOR), van Dongen, Guus A. M. S.^1,3 (AUTHOR), Vugts, Danielle^1,3 (AUTHOR) d.vugts@amsterdamumc.nl

Publikováno v: EJNMMI Radiopharmacy & Chemistry. 5/11/2024, Vol. 9 Issue 1, p1-21. 21p.

⁸⁹ Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.

Autor: Price EW; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Carnazza KE; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Carlin SD; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Cho A; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Edwards KJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Sevak KK; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Glaser JM; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., de Stanchina E; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Janjigian YY; Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; and., Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York lewisj2@mskcc.org.; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Sep; Vol. 58 (9), pp. 1386-1394. Date of Electronic Publication: 2017 Mar 09.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.